U.S. Markets close in 4 hrs 33 mins

Cadila Healthcare Limited (CADILAHC.BO)

BSE - BSE Real Time Price. Currency in INR
Add to watchlist
428.00+5.50 (+1.30%)
At close: 3:43PM IST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close422.50
Open420.00
Bid428.00 x 0
Ask428.25 x 0
Day's Range417.50 - 430.50
52 Week Range212.70 - 447.95
Volume118,854
Avg. Volume212,797
Market Cap438.161B
Beta (5Y Monthly)0.52
PE Ratio (TTM)33.04
EPS (TTM)12.95
Earnings DateN/A
Forward Dividend & Yield7.00 (1.66%)
Ex-Dividend DateMar 23, 2020
1y Target Est444.39
  • Reuters

    Zydus Cadila launches India's cheapest remdesivir version at $37 per vial

    Zydus Cadila on Thursday launched the cheapest generic version of Gilead Sciences' antiviral drug remdesivir in India to treat COVID-19 following reports of shortages at hospitals in the world's third-worst hit nation. Zydus has priced it at 2,800 rupees ($37.44) per 100mg vial. It will be sold under the brand name Remdac to government and private hospitals treating COVID-19 patients, the company said in a regulatory filing https://reut.rs/3gTivT4.

  • Zydus Cadila's COVID-19 vaccine candidate found safe in early-stage human trial
    Reuters

    Zydus Cadila's COVID-19 vaccine candidate found safe in early-stage human trial

    India's Zydus Cadila said on Wednesday its COVID-19 vaccine candidate was found to be safe and well-tolerated in an early-stage human trial. The company will now start a mid-stage trial of the vaccine candidate, ZyCoV-D, in over 1,000 healthy adult volunteers from Thursday to test its effectiveness, it said in a regulatory filing. The safety of the vaccine candidate in volunteers enrolled in the early-stage trial, who were administered doses since July 15, was endorsed by an independent data safety monitoring board.

  • Cadila aims to complete trial of coronavirus vaccine by March
    Reuters

    Cadila aims to complete trial of coronavirus vaccine by March

    India's Zydus Cadila plans to complete late-stage trials for its novel coronavirus vaccine candidate by February or March and could produce up to 100 million doses a year initially if it is successful, the company chairman said Friday. Cadila's vaccine candidate, known as ZyCov-D, is one of dozens being developed around the world to fight the coronavirus pandemic. "We are looking at about seven or a little more than seven months for the vaccine, provided the data is encouraging and the vaccine is proven to be effective during the trials," Chairman Pankaj Patel told Reuters in an interview.